Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case
| Autor: | M. A. Andreyanova, A. V. Pokrovsky, K. B. Mirzaev, D. A. Sychev, A. F. Kharazov, K. A. Ryzhikova |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Drug
medicine.medical_specialty type 2 diabetes mellitus media_common.quotation_subject ces1 CYP2C19 RM1-950 030204 cardiovascular system & hematology Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine cyp3a5 cyp3a4 medicine Diseases of the circulatory (Cardiovascular) system Pharmacology (medical) 030212 general & internal medicine cardiovascular diseases Omeprazole media_common pharmacogenetics clopidogrel CYP3A4 business.industry Type 2 Diabetes Mellitus Drug interaction Clopidogrel RC666-701 Therapeutics. Pharmacology atherosclerosis abcb1 Cardiology and Cardiovascular Medicine business cyp2c19 Pharmacogenetics medicine.drug p2y12 inhibitor |
| Zdroj: | Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 14, Iss 5, Pp 699-702 (2018) |
| ISSN: | 2225-3653 1819-6446 |
| Popis: | The considered clinical case of combination of multifocal atherosclerotic vascular lesion with type 2 diabetes mellitus and liver fibrosis demonstrates a combination of polyvalent risk factors for resistance to antiplatelet therapy with clopidogrel. The decrease in the effectiveness of prolonged therapy with P2Y 12 inhibitor was clinically manifested by repeated thrombotic events and was confirmed by laboratorial VerifyNow P2Y 12 Assay test system as a low percentage of inhibition of ADP-induced platelet aggregation. We established probable genetic predictors of the decrease in the effectiveness of antiplatelet therapy in this patient, namely, the carriage of polymorphic markers of the ABCB1 CT, CES1 CA and CYP3A4*22 CT genes that determine the decrease in absorption, excessive hydrolysis of the drug and reduced activity of isoenzymes and transporters, that leads to disorders of active clopidogrel metabolite formation. A potential contribution of hepatic dysfunction to reduction in antiaggregant effect of P2Y 12 inhibitor was demonstrated. Variant of drug interaction of clopidogrel and an inhibitor/substrate of P450 CYP2C19 – omeprazole, accompanied by a decrease in the effectiveness of antiplatelet therapy, was also considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|